[Use of a new water-soluble aldosterone-antagonist in surgery. Early clinical results].

A new i.v., water-soluble aldosterone antagonist (potassium canrenoate) was employed for the first time in a series of patients operated for various forms of abdominal disease. The pharmacological and clinical effects of the drug were constantly reproduced and a marked anti-aldosterone activity was noted. The drug is felt to be specifically indicated in the management of secondary hyperaldosteronism typical of the immediate postoperative period.